Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP).
Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP).
复制标题
DOI：
10.3390/bs4040511
复制
发表时间：
2014-12-08
期刊：
影响因子：
--
通讯作者：
Rothbaum B
中科院分区：
文献类型：
--
作者：
Dunlop BW;Kaye JL;Youngner C;Rothbaum B
创伤后应激障碍（PTSD）患者如果对现有的治疗方法没有反应，就有可能患上慢性残疾和痛苦。尽管难治性创伤后应激障碍（TR-PTSD）是一种常见的临床问题，但目前还没有标准方法来评估既往治疗结果。开发一种可以量化对先前提供的治疗的抵抗程度的工具将为PTSD患者的研究提供信息。我们对创伤后应激障碍治疗试验进行了系统回顾，以确定被证明对创伤后应激障碍有效的药物和心理治疗干预。然后，我们开发了一个半结构化的临床医生访谈，称为埃默里PTSD治疗阻力访谈（E-TRIP）。E-TRIP包括临床医生提出的问题，以评估既往治疗试验的充分性和获益。对于患者未能作出反应的每种充分提供的治疗，根据支持治疗疗效的证据强度进行评分。E-TRIP提供了对既往PTSD治疗的全面评估，这对于研究TR-PTSD和评估PTSD患者新治疗方法的疗效的研究人员来说是有价值的。E-TRIP不用于指导治疗;相反，该工具量化了PTSD患者的治疗抵抗水平，以便在研究领域标准化TR-PTSD。
Patients with posttraumatic stress disorder (PTSD) who fail to respond to established treatments are at risk for chronic disability and distress. Although treatment-resistant PTSD (TR-PTSD) is a common clinical problem, there is currently no standard method for evaluating previous treatment outcomes. Development of a tool that could quantify the degree of resistance to previously provided treatments would inform research in patients with PTSD. We conducted a systematic review of PTSD treatment trials to identify medication and psychotherapy interventions proven to be efficacious for PTSD. We then developed a semi-structured clinician interview called the Emory Treatment Resistance Interview for PTSD (E-TRIP). The E-TRIP includes clinician-administered questions to assess the adequacy and benefit derived from past treatment trials. For each adequately delivered treatment to which the patient failed to respond, a score is assigned depending on the strength of evidence supporting the treatment’s efficacy. The E-TRIP provides a comprehensive assessment of prior PTSD treatments that should prove valuable for researchers studying TR-PTSD and evaluating the efficacy of new treatments for patients with PTSD. The E-TRIP is not intended to guide treatment; rather, the tool quantifies the level of treatment resistance in patients with PTSD in order to standardize TR-PTSD in the research domain.